Abstract
The Epstein—Barr virus (EBV) is associated with malignancies that arise in both B lymphocytes and epithelial cells, including Burkitt’s lymphoma, immunodeficiency-related lymphoma, and nasopharyngeal carcinoma (NPC) (1,2). The malignancies associated with EBV develop years postinfection, suggesting that they represent some form of reactivated infection.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Raab-Traub N. Epstein—Barr virus and nasopharyngeal carcinoma. In: Rickinson A (eds). Seminars in Cancer Biology. Saunders Scientific Publishers, Academic Press, London, 1993, pp. 297–303.
Rickinson AB, Kieff E. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology, 3rd,edit., Vol. 2. Philadelphia: Lippincott-Raven, 1996, pp. 2397–2476.
de Thé G. Epidemiology of Epstein—Barr virus and associated diseases. In: Roizman B(eds). The Herpesviruses. New York: Plenum Press, 1982, pp. 25–87.
Ho JHC. Epidemiology of nasopharyngeal carcinoma (NPC). In: Ablashi DV, Huang AT, Pagano JS, Pearson GR, Yang CS (eds). Epstein—Barr virus and Human Disease. Humana Press, Totowa, NJ, 1990, pp. xli–xliv.
Pathmanathan R. Pathology. In: Chong VFH, Tsao SY (eds). Nasopharyngeal Carcinoma. Singapore: Armour, 1997, pp. 6–13.
Shanmugaratnam K, Chan SH, de Thé G, et al. Histopathology of nasopharyngeal carcinoma. Cancer 1979; 44: 1029–1044.
Henle G, Henle W. Epstein—Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17: 1–17.
Baskies AM, Chretien PB, Yan CS, et al. Serum glycoproteins and immunoglobulins in nasopharyngeal carcinoma: correlations with Epstein-Barr virus associated antibodies and clinical tumor stage. Am J Surg 1979; 138: 478–488.
Pearson GR, Weiland LH, Neel HB. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 1983; 51: 260–268.
Sam CK, Prasad U, Pathamanathan R. Serological markers in the diagnosis of histopathological types of nasopharyngeal carcinoma. Eur J Surg Oncol 1989; 15: 357–360.
Chen JY, Chen CJ, Liu MY et al. Antibodies to Epstein-Barr virus-specific Dnase in patients with nasopharyngeal carcinoma and control groups. J Med Virol 1987; 23: 11–21.
Littler E, Newman W, Arrand JR. Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr virus coded thymidine kinase expressed in Escherichia coli. Int J Cancer 1990; 45: 1028–1032.
Nonoyama M, Pagano, J. Homology between Epstein-Barr virus DNA and viral DNA from Burkitt’s lymphoma and nasopharyngeal carcinoma determined by DNA-DNA reassociation kinetics. Nature 1973; 242: 44–47.
Wolf H, zur Hausen H, Becker Y. EBV viral genomes in epithelial nasopharyngeal carcinoma cells. Nat Biol 1973; 244: 245–267.
Desgranges C, Wolf H, de, The G et al. Nasopharyngeal carcinoma X. Presence of Epstein-Barr virus genomes in epithelial cells of tumors from high and medium risk areas. Int J Cancer 1975; 16: 7–15.
Raab-Traub N, Flynn K, Pearson G, et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer 1987; 39: 25–29.
Chao TY, Chow KC, Chang JY, et al. Expression of Epstein-Barr virus-encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma. Cancer 1996; 78: 24–29.
Niedobitek G, Hansmann MI, Herbst H, et al. Epstein-Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J Pathol 1991; 165: 17–24.
Pathmanathan R, Prasad U, Chandrika G, et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995; 146: 1355–1367.
Stanley R. Clinical presentation and diagnosis. In: Chong VFH, Tsao SY (eds). Nasopharyngeal Carcinoma. Singapore, Armour, 1997.
Busson P, Ganem G, Flores P, Mugneret F, Clausse B, Caillou B, Braham K, Wakasugi H, Lipinski M, Tursz T. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 1988; 42: 599–606.
Raab-Traub N, Hood R, Yang CS, et al. Epstein-Barr virus transcription in nasopharyngeal carcinoma. J Virol 1983; 48: 580–590.
Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47: 883–889.
Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds). Virology. Philadelphia: Lippincott-Raven, 1996, pp. 2343–2396.
Kaschka-Dierich C, Adams A, Lindahl T, et al. Intracellular forms of Epstein-Barr virus DNA in human tumor cells in vivo. Nature 1976; 260: 302–306.
Given D, Yee D, Griem K, Kieff, E. DNA of Epstein-Barr virus. V. Direct repeats at the ends of Epstein-Barr virus DNA. J Virol 1979; 30: 852–862.
Kripalani-Joshi S, Law HY. Identification of integrated Epstein-Barr virus in nasopharyngeal carcinoma using pulse field gel electrophoresis. Int J Cancer 1994; 56: 187–192.
Busson P, McCoy R, Sadler R, et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 1992; 66: 3257–3262.
Gilligan K, Sato H, Rajadurai P, et al. Novel transcription from the Epstein-Barr virus terminal EcoR1 fragment, DlJhet, in a nasopharyngeal carcinoma. J Virol 1990; 64: 4948–4956.
Gilligan K, Rajadurai P, Lin JC, et al. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein preferentially expressed in epithelial cells. J Virol 1991; 65: 6252–6259.
Hitt MM, Allday MJ, Hara T, Karran L, Jones MD, Busson P, Tursz T, Ernberg I, Griffin BE. EBV gene expression in an NPC-related tumor. EMBO J 1989; 8: 2639–2651.
Sadler RH, Raab-Traub N. Structural analyses of the Epstein-Ban virus BamHI A transcripts. J Virol 1995; 69: 1132–1141.
Smith PR, Gao Y, Karran L, et al. Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors. J Virol 1993; 67: 3217–3225.
Fahraeus R, Fu JL, Ernberg I, Finke I, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, Tursz T, Kallin B. Expression of Epstein-Ban virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988; 42: 329–338.
Young L, Dawson C, Clark D, et al. Epstein-Barr virus expression in nasopharyngeal carcinoma. J Gen Virol 1988; 69: 1051–1065.
Stewart JP, Arrand JR. Expression of the Epstein-Barr virus latent membrane protein in nasopharyngeal carcinoma biopsy specimens. Hum Pathol 1993; 24: 239–242.
Cochet C, Martel-Renoir D, Grunewald V, et al. Expression of Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 1993; 197: 358–365.
Fries KL, Sculley TB, Webster-Cyriaque J, et al. Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J. Virol 1997; 71: 2765–2771.
Laux G, Dugrillon F, Eckert C, et al. Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. J Virol 1994; 68: 6947–6958.
Sung NS, Kenney S, Gutsch D, et al. EBNA2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol 1991; 65: 2164–2169.
Wang F, Tsang SF, Kurilla M, et al. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 1990; 54: 3407–3416.
Harada S, Kieff E. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 1997; 71: 6611–6618.
Robertson ES, Grossman S, Johannsen E, et al. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA binding protein, Jk. J Virol 1995; 69: 3108–3116.
Smith PR, Griffin BE. Transcription of Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells. J Virol 1992; 66: 706–714.
Sample J, Brooks L, Sample C, et al. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci USA 1991; 88: 6343–6347. 39.
Schaeffer BC, Woisetschlaeger M, Strominger JL, et al. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc Natl Acad Sci USA 1991; 88: 6550–6554.
Ernberg I, Falk K, Minarovits J, et al. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Virol 1989; 70: 2989–3002.
Sadler RH, Raab-Traub N. The Epstein-Barr virus 3.5 kilobase latent membrane protein 1 mRNA initiates from a TATA-less promoter within the first terminal repeat. J Virol 1995; 69: 4577–4581.
Srinivas SK, Sixbey J. Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol 1995; 69: 8155–8158.
Wilson J, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996; 15: 3117–3126.
Webster-Cyriaque J, Raab-Traub N. Transcription of Epstein-Barr virus latent cycle genes in oral hairy leukoplakia. Virology 1998; 248: 53–65.
Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685–688.
Kaye K, Izumi K, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993; 90: 9150–9154.
Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831–840.
Fries K, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996; 70: 8653–8659.
Kulwichit W, Edwards RH, Davenport E, et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B-cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998; 95: 11963–11968.
Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344: 777–780.
Fahraeus R, Chen W, Trivedi P, et al. Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells. Int J Cancer 1992; 52: 834–838.
Wilson JB, Weinberg W, Johnson R, et al. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990; 61: 1315–1327.
Miller WE, Earp HS, Raab-Traub N. The Epstein-Ban virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995; 69: 4390–4398.
Hu LF, Chen F, Zhen QF, et al. Differences in growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 1995; 31: 658–660.
Miller WE, Edwards RH, Walling DM, et al. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 1993; 75: 2729–2740.
Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389–399.
Huen DS, Henderson SA, Croom-Carter D, et al. The Epstein-Ban virus latent membrane protein 1 (LMP1) mediates activation of NFkB and cell surface phenotype via two effector regions in its carboxy terminal cytoplasmic domain. Oncogene 1995; 10: 549–560.
Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998; 16: 1731–1742.
Paine E, Scheinman RI, Baldwin Jr AS, et al. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-iB/Rel family proteins. J Virol 1995; 69: 4572–4576.
Miller WE, Cheshire JL, Raab-Traub N. Interaction of Tumor Necrosis factor signaling proteins with the latent membane protein PxQxt motif is essential for induction of epidermal growth factor receptor expression. Mol Cell Biol 1998; 18: 2835–2844.
Frech B, Zimber-Strobl U, Yip TTC, et al. Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. J Gen Virol 1993; 74: 811–818.
Longnecker R, Kieff E. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol 1990; 64: 2319–2326.
Miller CL, Lee JH, Kieff E, et al. An integral membrane protein (LMP2) blocks reactivationof Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA 1994; 91: 772–776.
Scholle F, Longnecker R, Raab-Traub N. Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal src kinase. J Virol 1999; 73: 4767–4775.
Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene expression in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66: 2689–2697.
Arrand JR, Rymo L. Characterization of the major Epstein-Barr virus-specific RNA in Burkitt lymphoma-derived cells. J Virol 1982; 41: 376–389.
Swaminathan S, Tomkinson B, Kieff E. Recombinant Epstein-Barr virus deleted for small RNA (EBER) genes transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci USA 1991; 88: 1546–1550.
Tsai ST, Jin YT, Su IJ, Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization: a correlation with WHO histologic subtypes. Cancer 1996; 77: 231–236.
Gilligan K, Rajadurai P, Resnick L, et al. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci USA 1990; 87: 8790–8794.
Raab-Traub N, Pritchett R, Kieff E. DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments which contain DNA sequences which differ among strains of EBV. J Virol 1978; 27: 388–398.
Sato H, Takimoto T, Hatano M, et al. Epstein-Barr virus with transforming and early-antigen inducing ability originating from nasopharyngeal carcinoma. J Gen Virol 1989; 70: 717–727.
Rowe M, Young L, Cadwallader K, et al. Distinction between Epstein-Barr virus type-A (EBNA-2A) and type-B (EBNA-2B) isolates extends to the EBNA-3 family of nuclear proteins. J Virol 1989; 63: 1031–1039.
Sample J, Young L, Martin B, et al. Epstein-Barr virus type 1 and type 2 differ in their EBNA3A, EBNA-3B and EBNA-3C genes. J Virol 1990; 64: 4084–4092.
Walling D, Edmiston SN, Sixbey, JW, et al. Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia. Proc Natl Acad Sci USA 1992; 89: 6560–6564.
Lung M, Chang R, Huang M, et al. Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China. Virology 1990; 177: 44–53.
Abdel-Hamid M, Chen JJ, Constantine N, et al. EBV strain variation: geographical distribution and relation to disease state. Virology 1992; 190: 168–175.
Hu LF, Zabarovsky ER, Chen F, et al. Isolation and sequencing of the Epstein-Barr virus BNLF-1 (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991; 72: 2399–2409.
Sample J, Kieff EF, Kieff ED. Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes. J Gen Virol 1994; 75: 2741–2746.
Knecht H, Bachmann E, Brousset P, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin’s disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993; 82: 2937–2942.
Li SN, Chang YS, Liu ST. Effect of a 10 amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein Barr virus. Oncogene 1996; 12: 2129–2135.
Miller WE, Cheshire JL, Baldwin AS, et al. The NPC derived C15 LMP1 protein confers enhanced activation of NF-KB and induction of the EGFR in epithelial cells. Oncogene 1998; 16: 1869–1877.
Edward RH, Seillier-Moiseiwitsch F, Raab-Traub N. Signature amino acid changes in LMP1 distinguish Epstein-Barr virus strains. Virology 1999; 261: 79–95.
Walling DM, Shebib N, Weaver SC, et al. The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane protein 1. J Infect Dis 1999; 179: 763–774
Sixbey J, Vesterinen EH, Nedrud JG, et al. EBV replication in human epithelial cells infected in vitro. Nature 1983; 306: 480–483.
Li QX, Young LS, Niedobitek G, et al. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 1992; 356: 347–350.
Imai, S, Nishikawa, J, Takada, K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Viro! 1998; 72: 4371–4378.
Sixbey JW, Yao QY. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 1992; 255: 1578–1580.
Gan YJ, Chodosh J, Morgan A, et al. Epithelial cell polarization is a determinant in the infectious outcome of immunoglobulin A-mediated entry by Epstein-Barr virus. J Virol 1997; 71: 519–526.
Zhang Q, Gutsch D, Kenney S. Functional and physical interaction between p.53 and BZLFI: implications for Epstein-Barr virus latency. Mol Cell Biol 1994; 14: 1929–1938.
Wei MX, Moulin JC, Decaussin G, et al. Expression and tumorigenicity of the Epstein-Barr virus BARF1 gene in human Louckes B-lymphocyte line. Cancer Res 1994; 54: 1843–1848.
Lemon SM, Hutt LM, Shaw JE, et al. Replication of EBV in epithelial cells during infectious mononucleosis. Nature 1977; 268: 268–270.
Sixbey J, Nedrud JG, Raab-Traub N, et al. Detection of Epstein-Barr virus DNA and RNA in human pharyngeal epithelial cells. N Engl J Med 1984; 310: 1225–1230.
Wolf H, Haus M, Wilmes E. Persistence of Epstein-Barr virus in the parotid gland. J Virol 1984; 51: 795–798.
Wen S, Mizugaki Y, Shinozaki F, et al. Epstein-Barr virus (EBV) infection in salivary gland tumors: lytic EBV infection in non-malignant epithelial cells surrounded by EBV-positive T-lymphoma cells. Virology 1997; 227: 484–487.
Tao Q, Srivastava G, Chan ACL. Evidence for lytic infection by Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. J Med Virol 1995; 45: 71–77.
Desgrange C, Bornkam GW, Zeng Y, et al. Detection of Epstein-Barr viral DNA internal repeats in the nasopharyngeal mucosa of Chinese with IgA/EBV-specific antibodies. Int J Cancer 1982; 29: 87–91.
Yeung WM, Zong YS, Chiu CT, et al. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer 1993; 53: 746–750.
Pathmanathan R, Prasad U, Sadler RH, Flynn K, Raab-Traub N. Preinvasive neoplasia of the nasopharynx: a clonal proliferation of EBV-infected cells. N Engl J Med 1995; 333: 695–698.
Armstrong RW, Armstrong MH, Yu MC, et al. Salted fish and inhalants as risk factors for carcinoma in Malaysian Chinese. Cancer Res 1983; 43: 2967–2970
Ning JP, Yu MC, Wang QS, Henderson BE. Consumption of salted fish and other risk factors for nasopharyngeal carcinoma in Tianjink, a low risk region of China. J Natl Cancer Inst 1990; 82: 291–296.
Poirier S, Ohshima H, De The G, Hubert A, Bourgade MC, Bartsch H. Volatiale nitrosamine levels in common foods from Tunisia, South China, and Greenland, high risk areas for nasopharyngeal carcinoma (NPC). Int J Cancer 1987; 39: 292–296.
Lanier AP, Henle W, Bender TR, et al. Nasopharyngeal carcinoma in Alaskan Eskimos, Indians, and Aleuts: a review of cases and study of Epstein-Barr virus, HLA, and environmental risk factors. Cancer 1980; 46: 2100–2106.
Lu SJ, Degos NE, Lepage V, et al. Linkage of a nasopharyngeal susceptibility locus to the HLA region. Nature 1990; 346: 470–471.
Murray PG, Niedibitek G, Kremmer E, et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positve malignancies. J Exp Med 1992; 176: 157–168.
Burt RD, Vaughan TL, Nisperos B, et al. A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians. Int J Cancer 1994; 56: 465–467.
Eifert P, McCoy R, Abdel-Hamid M, Flynn K, et al. Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 1992; 66: 3768–3775.
Sun Y, Hegameyer G, Colburn N. Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. Oncogene 1993; 8: 791–795.
Sun Y, Hildesheim A, Lanier AP, et al. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinoma. Oncogene 1995; 10: 765–788.
Niedobitek G, Agathanggelou A, Barber P, et al. Overexpression and Epstein—Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol 1993; 170: 457–461.
Okan I, Wang Y, Chen F, et al. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 1995; 11: 1027–1031.
Henderson S, Rowe M, Gregory C, et al. Induction of bd-2 expression by Epstein—Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107–1115.
Lu QL, Elia G, Lucas S, et al. Bd-2 proto-oncogene expression in Epstein—Ban-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993; 53: 29–35.
Huang D, Lo KW, Choi PHK, et al. Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma. Cancer Genet Cytogenet 1991; 54: 91–99.
Huang D, Lo KW, van Hasselt A, et al. A region of homozygous deletion on chromosome 9p21–22 in primary nasopharyngeal carcinoma. Cancer Res. 1994; 54: 4003–4006.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Raab-Traub, N. (2000). Epstein-Barr Virus and Nasopharyngeal Carcinoma. In: Goedert, J.J. (eds) Infectious Causes of Cancer. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-024-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-59259-024-7_6
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9621-5
Online ISBN: 978-1-59259-024-7
eBook Packages: Springer Book Archive